Keyphrases
Relapsing-remitting multiple Sclerosis
100%
Peginterferon
100%
Interferon-α (IFN-α)
71%
Annualized Relapse Rate
42%
Magnetic Resonance Imaging
28%
Dosing Regimen
28%
Treatment Effect
14%
Placebo
14%
Placebo-controlled
14%
Polyethylene Glycol
14%
N-terminus
14%
Imaging Results
14%
Positive Impact
14%
Modified Forms
14%
Disability Progression
14%
Pharmacokinetic Properties
14%
Pharmacodynamic Properties
14%
Amino Group
14%
Number of Injections
14%
Adverse Effect Profile
14%
Long-term Adherence
14%
Gadolinium-enhancing Lesions
14%
T2 Lesions
14%
Reduced Frequency
14%
Reduced Immunogenicity
14%
Imaging Endpoints
14%
Pharmacology, Toxicology and Pharmaceutical Science
Base
100%
Multiple Sclerosis
100%
Peginterferon
100%
Interferon
71%
Recurrence Risk
42%
Placebo
28%
Adverse Event
14%
Immunogenicity
14%
Pharmacodynamics
14%
Pharmacokinetics
14%
Macrogol
14%
Gadolinium
14%